It has been less than a week since the landmark study into the genetics of same-sex sexual behaviour first broke and sparked debate across the twitterverse. There has been much disagreement amongst the scientific and LGBTQ+ communities alike, regarding whether this research should have been conducted at all. Conversely, many have praised the study for […]
The Digital DNA series explores the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. We talked to Jill Davies, CEO of GeneMatters. The company provides genetic counselling to patients through a telehealth platform […]
The Digital DNA series explores the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. When Ralph Taylor registered his new business, he attempted to declare it as a disadvantaged business enterprise. Businesses headed […]
Consumer genomics company Ancestry has launched the new upgrade to its AncestryDNA experience, Ancestry Communities. Contrary to many commercial DNA sites, Communities promises to specify UK users’ genetic ancestry to a county level.
The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.
GEDMatch, the DNA database which made news recently for its instrumental role in solving cold criminal cases in the US, has blocked law enforcement from accessing information for the millions of people on its system.
uBiome, a Silicon Valley startup providing tests focussing on the microbiome and its importance to health, is under investigation after an FBI raid on its offices over how it was allegedly billing its customers. The company has received significant criticism recently for handling of the cofounders’ relationship and alleged corner-cutting during its scientific work.
Genetic research is a big data problem without researchers generally having access to this “big” genomic and medical data. Not only has it been nearly impossible to access enough relevant data to support research, but analysing the data has been slow and challenging due to its sheer volume. To counter this, in recent years a number of pharmaceutical companies have announced large-scale collaborations around genomic data to uncover novel drug targets, validate existing drug pipelines, predict response, and expand therapeutics use. We discuss some of the biggest and most recent.
Genomic compression expert PetaGene has become a NetApp Alliance Partner, the company announced recently, a move set to improve performance and reduce costs for researchers using large datasets within the genomics field.
SOPHiA GENETICS’ Solid Tumor Solution (STS) application was recently granted a CE-IVD designation, a regulatory stamp that a product has satisfied the EU’s in vitro diagnostic device requirements. We spoke to Gioia Althoff, SOPHiA’s Senior Vice President, Genomics Business Area, about the STS application and where SOPHiA is going from here.
Compression software company Petagene has announced the addition of “Petagene Protect” to its suite of genomic data projects, giving users the ability to encrypt and manage access to genomic data, as well as ensuring compliance with all relevant regulations.
Amazon has announced that new software for its Alexa virtual assistant will allow healthcare companies to build tools which can safely send private information to patients. The announcement was accompanied by the launch of six voice programs created by health companies including Boston Children’s Hospital and digital health company Livongo.
Commercial DNA-analysing company 23andMe is looking to launch a new DNA assessment to help individuals discover their risk of developing type 2 diabetes. Several million customers will receive the information over the coming weeks.
Roche is set to pay $4.3bn for the acquisition of Spark Therapeutics, a gene therapy company that will put the pharma giant ahead in one of the biggest growing markets around.